Hemispherx, Quest Pharma deal

Quest and Hemispherx partnered to evaluate Quest's cancer candidate oregovomab with Hemispherx's Ampligen rintatolimod to treat advanced ovarian cancer in a Phase I/II trial. The partners will equally split the $1 million cost of the trial, while Hemispherx will provide relevant data to support the regulatory process necessary to conduct the clinical trial. The U.S. and Canadian trial comparing Ampligen plus oregovomab vs. Ampligen alone in 30 patients is expected to begin mid-year. ...